4 FDA approvals this Q (Mcap 96 Mil) Hot Pick 2011

[BiotechMaster]

With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.

2011 Price Target: $25.00+ .Get in now before the stock gets Discovered .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Anika is a once in a lifetime opportunity .GLTA


Anika Therapeutics (ANIK)

Market-Cap: 96 Mil
Cash: 26 Mil
Price: 7.20

Shares Out: 13.5


UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



Big Pipeline
Anika Therapeutics &ndash; Pipeline


Insider Ownership
ANIK: ANIKA THERAPEUTICS INC Institutional Ownership


Anika Therapeutics &ndash; Spotlight

FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:

* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;

* Hyalonect®, a knitted mesh used as a bone graft wrap; and

* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.

We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.

Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.

[BiotechMaster]

Load up before the stock moves into double digits .Anything below 12$ is a pure gift . GL


ANIK - Anika Therapeutics Inc., Stock Quote, Analysis, Rating and News

Resistance1: 9.78
Resistance2: 11.42

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[BiotechMaster]

This stock is still significantly Undervalued . Anik awaiting 4 FDA approvals including one potential Blockbuster(Monovisc) , the first Approval could push this stock to $15+ .I think we could see $30+ with all FDA approvals . Anika is definitely one of the best Biotech Investment .GL

Gallery View - StockCharts.com - Free Charts

[FavStocks]

You have been making some excellent calls BiotechMaster. Great work!!

[BiotechMaster]

@Favstock

Thank you .



Anik is still significantly undervalued .The first FDA approval is around the corner to push us into Double digits .



Anika Therapeutics (ANIK)

Market-Cap: 125 Mil
Cash: 26 Mil
Price: 9.33

Shares Out: 13.5



UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:

* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;

* Hyalonect®, a knitted mesh used as a bone graft wrap; and

* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.

We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.

Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.

[ljdavis]

8.32 pps.. load up

[BiotechMaster]

The ANIK is story is full intact all 510k/PMA application are under review by FDA NOTHING has changed NO DELAY NO BAD NEWS .

Institutions bought a lot of shares in the last few days (~ 1 Mil Shares) . Do you think the institutions would invest in a stock if there is no Potential ???? NEVER

I think the drop was a manipulation because there is no real bad news .


Anika Therapeutics Inc. (ANIK) Real-Time SEC Filings - NASDAQ.com



Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2010 Financial Results Conference Call and Provides Regulatory Timing Update - Yahoo! Finance

[ljdavis]

on the way back up.. good flip coming if you got in from 8.01-8.3 yesterday

[pignit]

Sad, I got it one day earlier at $9.35...

on the way back up.. good flip coming if you got in from 8.01-8.3 yesterday

[Angeliqua]

What do you think about VRML?